Compare GOSS & CTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOSS | CTM |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.2M | 93.7M |
| IPO Year | 2018 | 2022 |
| Metric | GOSS | CTM |
|---|---|---|
| Price | $0.40 | $0.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $4.19 | $3.00 |
| AVG Volume (30 Days) | ★ 26.2M | 660.2K |
| Earning Date | 03-17-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.33 |
| EPS | N/A | ★ N/A |
| Revenue | $48,471,000.00 | ★ $52,866,001.00 |
| Revenue This Year | N/A | $16.55 |
| Revenue Next Year | $203.01 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.10 |
| 52 Week Low | $0.33 | $0.77 |
| 52 Week High | $3.87 | $1.56 |
| Indicator | GOSS | CTM |
|---|---|---|
| Relative Strength Index (RSI) | 23.42 | 26.82 |
| Support Level | $0.33 | N/A |
| Resistance Level | $0.60 | $0.99 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 0.00 | 2.97 |
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Castellum Inc is engaged in providing information technology services. The company provides financial services, healthcare, and other users of large data applications with services that include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and MBSE. In addition to constantly innovating and enhancing organic capabilities, Castellum is acquiring technology companies in the areas of cybersecurity, information technology, electronic warfare, information warfare, and information operations with businesses in the defense, federal, civilian, and commercial markets.